Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01119209
Other study ID # S-VF-20060072 - trochanteric
Secondary ID
Status Completed
Phase Phase 4
First received May 4, 2010
Last updated March 15, 2011
Start date February 2008
Est. completion date January 2011

Study information

Verified date March 2011
Source Odense University Hospital
Contact n/a
Is FDA regulated No
Health authority Denmark: Danish Medicines Agency
Study type Interventional

Clinical Trial Summary

Reducing pain is an essential factor for early mobilization after osteosynthesis of intertrochanteric fractures. Systemic opioids have side effects that might obstruct mobilization and induce delirium and nausea. The investigators hypothesized that wound infiltration results in reduction in systemic opioid usage and pain relief without side effects.


Recruitment information / eligibility

Status Completed
Enrollment 74
Est. completion date January 2011
Est. primary completion date January 2011
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Intertrochanteric hip fracture

- Fracture due to low energy trauma

- Ability to understand danish and give informed consent

- Ability to walk before trauma

- Indication for osteosynthesis

•= 8 in OMC (Orientation-Memory-Concentration) test with a possible maximum of 28 points

- Informed consent

Exclusion Criteria:

- Drug or medical abuse

- Drug intolerance

- Pathological fractures

- Inflammatory arthritis

- Patient included in the study with the contralateral hip

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Ropivacaine
Approved by the Danish Medicines Agency
Saline
Approved by the Danish Medicines Agency

Locations

Country Name City State
Denmark Odense University Hospital Odense DK

Sponsors (1)

Lead Sponsor Collaborator
Odense University Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Consumption of opioids 5 days postoperatively No
Secondary Pain 5 days postoperatively No